Evaluation of clinical pharmacists’ follow-up service in an oncology pain clinic

Ryan, Nikki; Chambers, Carole; Ralph, Christopher; England, Dean; Cusano, Frances

doi:10.1177/1078155212457805

Cited by 19 publications

(13 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…3 Reports have been published that describe the role of a pharmacist in palliative care and provide pilot data on evaluating the benefit and effectiveness of services offered. [4][5][6][7][8] However, no report was identified from a center in the Middle East or Gulf Cooperation Council (GCC). The GCC is a political and economic union of Arab states bordering the Persian Gulf, namely, Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and the United Arab Emirates.…”

Section: Introductionmentioning

confidence: 94%

Evaluation of Clinical Pharmacy Services Offered for Palliative Care Patients in Qatar

Wilby

Mohamad²,

Alyafei³

2014

Journal of Pain & Palliative Care Pharmacotherapy

View full text Add to dashboard Cite

Palliative care is an emerging concept in the countries of the Gulf Cooperation Council, a political and economic union of Arab states bordering the Persian Gulf, namely Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and the United Arab Emirates. Clinical pharmacy services have not yet been evaluated in this region. The objectives of this study were to create a baseline inventory of clinical pharmacy interventions in palliative care and to assess the perceived importance of interventions made. This was a prospective, single-center characterization study. Interventions were documented from September 30 to December 1, 2013. They were characterized into predetermined categories and analyzed using descriptive statistics. Physician acceptance rate and intervention rate per patient were calculated. Classification categories were sent to 10 practicing pharmacists in each of Qatar and Canada, who ranked the categories on the basis of perceived importance. A total of 96 interventions were documented, giving 3 interventions per patient and an acceptance rate of 81%. Discontinuing therapy (29%), initiating therapy (25%), and provision of education/counseling (13.5%) were most common. No differences were found between rankings from pharmacists in Qatar or Canada. Clinical pharmacy interventions are frequent, and those relating to alterations in drug therapy are most common. Interventions align with the perceived importance from pharmacists in both Qatar and Canada.

show abstract

Section: Introductionmentioning

confidence: 94%

Evaluation of Clinical Pharmacy Services Offered for Palliative Care Patients in Qatar

Wilby

Mohamad²,

Alyafei³

2014

Journal of Pain & Palliative Care Pharmacotherapy

View full text Add to dashboard Cite

show abstract

“…Studies have shown that a clinical pharmacist involved in a multidisciplinary treatment team applying IMM, may identify a high number of DRPs 8–10. Previous studies have demonstrated that clinical pharmacists can improve supportive treatment for pain and gastrointestinal disturbance among cancer patients 11 12. Cytotoxic, biological and immune system-modulating drugs caused 31% of the fatal adverse events reported to the Norwegian Medicines Agency in 2011 13.…”

Section: Introductionmentioning

confidence: 99%

Pharmacist assessment of drug-related problems on an oncology ward

Cehajic¹,

Bergan

Bjordal

2015

Eur J Hosp Pharm

View full text Add to dashboard Cite

Objectives Cancer patients have a high incidence of concurrent chronic diseases, the pharmacological treatment of which is generally complex and carries an inherent risk of drug-related problems (DRPs). DRPs can interfere with the patient's health outcomes. No systematic investigation of the prevalence of DRPs in hospitalised cancer patients has been performed in Norway. The aim of this study was to characterise the DRPs on an oncology ward, using systematic medication review, and to suggest interventions to optimise drug therapy. Methods A clinical pharmacist applying the integrated medicines management method reviewed the drug treatment of 48 in-patients. The identified DRPs and the interventions proposed by the clinical pharmacist were discussed with the oncologists and oncology nurses, and the conclusions were characterised. Results 100 DRPs were identified through medication review. Of these, 41% were identified in the medication charts, 21% by evaluating the choice of drug and 21% by evaluating drug dosing. 75% of the suggested interventions for DRPs were implemented in the drug therapy of the patients.Conclusions The results of this study demonstrate that the suggested interventions for reducing DRPs were frequently implemented by oncologists. The results also demonstrate that a clinical pharmacist, using medication review on an oncology ward, probably can improve the quality of the drug treatment of hospitalised cancer patients. BACKGROUND

show abstract

“…Patients identified through the electronic health record as completing the AINV tool were approached to complete a patient and parent/caregiver satisfaction survey. Surveys questions were created with the assistance of a clinical psychologist, using previous published survey questions [8][9][10] and adopted for appropriate pediatric age ranges based on the format in the PedsQL version 4.0. [11][12][13] Questionnaires were administered by a pharmacy student at the time of follow-up visits.…”

Section: Patientsmentioning

confidence: 99%

Integration of a nausea and vomiting assessment tool into antineoplastic management of pediatric oncology patients

McKinnon

Jupp

2019

J Oncol Pharm Pract

View full text Add to dashboard Cite

Background Antineoplastic-induced nausea and vomiting (AINV) is a treatment-related issue that can have significant negative influences on the cancer patient’s quality of life. Assessment of nausea is challenging in children as few studies include the perception of nausea as an outcome, and the severity is rarely evaluated with the use of a validated instrument. We describe our experience of integrating an AINV tool into patient care at the Alberta Children’s Hospital. Procedure: The Pediatric Nausea Assessment Tool (PeNAT) was adapted to create a standardized tool that could be used by the clinical pharmacists for AINV assessment. From February to August 2017, 74 patients receiving 217 cycles of highly or moderately emetogenic chemotherapy (HEC or MEC) were eligible to use the AINV tool. Patients that completed the AINV tool were contacted to complete a satisfaction survey. Results AINV tool uptake was low: 47 (22%) eligible chemotherapy cycles utilized the tool (24 (32%) and 23 (16%) cycles of HEC and MEC, respectively, ( p < 0.01)). Ifosfamide-containing cycles received the highest nausea ratings, with nausea severity correlated with agent emetogenicity. Mean nausea rating was 2.07 versus 1.76 for patients receiving HEC or MEC, respectively. Clinical pharmacists performed 1.24 AINV interventions per day. Patient satisfaction with AINV care overall was high; however, 51% of patients indicated that the tool led to no changes in nausea symptoms. Conclusions AINV tool uptake was low with limited value in improving outcomes. Incorporation of nausea assessment into the electronic health record and potential use of a mobile application may improve uptake.

show abstract

Evaluation of clinical pharmacists’ follow-up service in an oncology pain clinic

Abstract: The inclusion of pharmacists in the Pain and Symptom Control Clinic is favored by patients and health care professionals and provides increased efficiency to the clinic.

Cited by 19 publications

References 6 publications

Evaluation of Clinical Pharmacy Services Offered for Palliative Care Patients in Qatar

Evaluation of Clinical Pharmacy Services Offered for Palliative Care Patients in Qatar

Pharmacist assessment of drug-related problems on an oncology ward

Integration of a nausea and vomiting assessment tool into antineoplastic management of pediatric oncology patients

Contact Info

Product

Resources

About